|
|
Executive Committee of the CEO Roundtable on Cancer
|
William C. Weldon
Immediate Past Chairman, CEO Roundtable on Cancer
Chairman of the Board and Chief Executive Officer, Johnson & Johnson |
|
Robert A. Ingram
Past Chairman and Co-Founder, CEO Roundtable on Cancer
Vice Chairman, Pharmaceuticals, GlaxoSmithKline |
|
H. Edward Hanway
Treasurer, CEO Roundtable on Cancer
Chief Executive Officer, CIGNA |
Life Sciences Consortium Task Force Leadership
|
Gregory A. Curt, M.D.
Chairman, Life Sciences Consortium Task Force
US Medical Science Lead for Emerging Products, AstraZeneca Oncology |
|
Mace L. Rothenberg, M.D.
Vice Chairman, Life Sciences Consortium Task Force
Senior Vice President of Clinical Development and Medical Affairs for the Oncology Business Unit at Pfizer’s Global Research and Development |
CEO Roundtable on Cancer Staff
|
|
Access to standardized legal language for Key elements can increase the efficiency of contract negotiations, resulting in reduced costs and accelerating the entry of new therapies into clinical trials. |
|
|
|
|